Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-19T12:16:00.870Z Has data issue: false hasContentIssue false
  • English
  • Français

P01-37 - Effects of Testosterone Supplementation on Depressive Symptoms in Hypogonadal men with the Metabolic Syndrome: The Moscow Study

Published online by Cambridge University Press:  17 April 2020

E.J. Giltay ,
Y.A. Tishova ,
G.J. Mskhalaya ,
L.J.G. Gooren ,
F. Saad  and
S.Y. Kalinchenko
E.J. Giltay
Affiliation:
Psychiatry, Leiden University Medical Center (LUMC), Leiden, The Netherlands
Y.A. Tishova
Affiliation:
Andrology and Urology, Scientific Center for Endocrinology, Moscow, Russia
G.J. Mskhalaya
Affiliation:
Andrology and Urology, Scientific Center for Endocrinology, Moscow, Russia
L.J.G. Gooren
Affiliation:
Endocrinology, VU University Medical Center, Amsterdam, The Netherlands
F. Saad
Affiliation:
Bayer Schering Pharma, Scientific Affairs Men's Healthcare, Berlin, Germany
S.Y. Kalinchenko
Affiliation:
Clinical Andrology, People's Friendship University of Russia, Moscow, Russia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Low testosterone levels in men are associated with the metabolic syndrome (MetS) as well as with depressive symptoms, low vitality and sexual dysfunction.

Objectives

To assess the effects of testosterone administration on these subjective symptoms, which have not extensively been studied in hypogonadal men with the MetS.

Method

In a randomized, placebo-controlled, double-blind, phase III trial, 184 men suffering from both the MetS and hypogonadism were included. They were treated for 30 weeks with either parenteral testosterone undecanoate (TU; 1000 mg IM testosterone undecanoate, at baseline, and after 6 and 18 weeks; Nebido®) or placebo injections. 105 (92.9%) men receiving TU and 65 (91.5%) receiving placebo completed the 30 week trial. The Beck Depression Inventory (BDI), Aging Males’ Symptoms (AMS) scale, and International Index of Erectile Function 5-item (IIEF-5) scale at baseline, 18 and 30 weeks were analysed using multilevel analysis.

Results

The mean age was 52.1 years (range: 35-69), with a mean body mass index of 35.5 kg/m2 (SD 6.7), and a mean total testosterone level of 8.0 nmol/L (SD 4.0). There were significant improvements in BDI (mean difference vs. placebo after 30 weeks: -2.5 points; 95% confidence interval [CI]: -0.9;-4.1; P=0.003), AMS (-7.4 points; 95% CI: -4.3;-10.5; P< 0.001), and IIEF-5 (+3.1 points; 95% CI: +1.8;+4.4; P< 0.001). The effects were strongest in men with baseline total testosterone levels < 7.7 mmol/L.

Conclusions

TU administration may improve depressive symptoms, aging male symptoms and sexual dysfunction in hypogonadal men with the MetS.

Type
Affective disorders / Unipolar depression / Bipolar disorder
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E256
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.